The Cooper Companies, Inc. (COO) 10-Q 5 Sep 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Jul. 31, 2014
Document And Entity Information [Abstract]	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	31-Jul-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q3
Entity Registrant Name	'COOPER COMPANIES INC
Entity Central Index Key	'0000711404
Current Fiscal Year End Date	'--10-31
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	48,282,203

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Income Statement [Abstract]	'	'	'	'
Net sales	$432,482	$411,993	$1,249,779	$1,175,873
Cost of sales	151,892	143,719	437,761	412,923
Gross profit	280,590	268,274	812,018	762,950
Selling, general and administrative expense	161,203	152,141	475,095	453,487
Research and development expense	16,070	14,865	48,077	43,008
Amortization of intangibles	6,752	7,660	21,735	22,553
Operating income	96,565	93,608	267,111	243,902
Interest expense	1,499	2,258	4,713	7,268
Gain on insurance proceeds	0	0	0	14,084
Other expense (income), net	683	86	739	-461
Income before income taxes	94,383	91,264	261,659	251,179
Provision for income taxes	5,711	2,072	21,087	11,585
Net income	88,672	89,192	240,572	239,594
Less: income attributable to noncontrolling interests	605	241	1,502	840
Net income attributable to Cooper stockholders	$88,067	$88,951	$239,070	$238,754
Earnings per share attributable to Cooper stockholders - basic	$1.83	$1.82	$4.98	$4.91
Earnings per share attributable to Cooper stockholders - diluted	$1.80	$1.79	$4.89	$4.81
Number of shares used to compute earnings per share:	'	'	'	'
Basic	48,042	48,791	47,990	48,588
Diluted	48,922	49,754	48,901	49,623

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$88,672	$89,192	$240,572	$239,594
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation adjustment	-8,989	-12,697	14,168	-26,108
Change in value of derivative instruments, net of tax provision of $144 and $541 for the three and nine months ended July 31, 2014, respectively, and $260 and $647 for the corresponding periods of fiscal 2013, respectively	225	406	846	1,013
Change in minimum pension liability, net of tax	7	7	22	22
Unrealized (loss) gain on marketable securities, net of tax provision of $0 for the three and nine months ended July 31, 2014, and $(3) and $22 for the corresponding periods of fiscal 2013, respectively	0	-5	0	41
Reclassification of realized gain on marketable securities to net income, net of tax provision of $0 for the three and nine months ended July 31, 2014 and $(51) for both the corresponding periods of fiscal 2013, respectively	0	-95	0	-95
Other comprehensive (loss) income	-8,757	-12,384	15,036	-25,127
Comprehensive income	79,915	76,808	255,608	214,467
Comprehensive (income) loss attributable to noncontrolling interests	-471	114	-1,118	740
Comprehensive income attributable to Cooper stockholders	$79,444	$76,922	$254,490	$215,207

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Change in value of derivative instruments, tax	$144	$260	$541	$647
Minimum Pension Liability, tax	0	0	0	0
Unrealized gain on marketable securities, tax	0	-3	0	22
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax	$0	($51)	$0	($51)

Consolidated_Condensed_Balance

Consolidated Condensed Balance Sheets (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$173,786	$77,393
Trade accounts receivable, net of allowance for doubtful accounts of $5,259 at July 31, 2014 and $5,261 at October 31, 2013	261,964	229,537
Inventories	353,384	338,917
Deferred tax assets	39,445	41,179
Prepaid expense and other current assets	67,234	60,215
Total current assets	895,813	747,241
Property, plant and equipment, at cost	1,420,878	1,240,576
Less: accumulated depreciation and amortization	577,465	500,709
Property, plant and equipment, net	843,413	739,867
Goodwill	1,390,911	1,387,611
Other intangibles, net	176,292	198,769
Deferred tax assets	18,633	16,279
Other assets	42,312	47,494
Total assets	3,367,374	3,137,261
Current liabilities:	'	'
Short-term debt	46,492	42,987
Accounts payable	87,209	108,172
Employee compensation and benefits	59,517	63,414
Other current liabilities	104,469	106,680
Total current liabilities	297,687	321,253
Long-term debt	301,449	301,670
Deferred tax liabilities	26,152	24,883
Accrued pension liability and other	65,809	65,961
Total liabilities	691,097	713,767
Commitments and contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, 10 cents par value, shares authorized: 1,000; zero shares issued or outstanding	0	0
Common stock, 10 cents par value, shares authorized: 120,000; issued 50,964 at July 31, 2014 and 50,335 at October 31, 2013	5,097	5,034
Additional paid-in capital	1,375,314	1,329,329
Accumulated other comprehensive loss	-726	-15,762
Retained earnings	1,548,037	1,311,851
Treasury stock at cost: 2,682 shares at July 31, 2014 and 2,340 shares at October 31, 2013	-270,649	-225,917
Total Cooper stockholders' equity	2,657,073	2,404,535
Noncontrolling interests	19,204	18,959
Stockholders’ equity	2,676,277	2,423,494
Total liabilities and stockholders' equity	$3,367,374	$3,137,261

Consolidated_Condensed_Balance1

Consolidated Condensed Balance Sheets (Parenthetical) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Trade accounts receivable, allowance for doubtful accounts	$5,259	$5,261
Preferred stock, par value	$0.10	$0.10
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares, issued	50,964,000	50,335,000
Treasury stock, shares	2,682,000	2,340,000

Consolidated_Condensed_Stateme

Consolidated Condensed Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013
Cash flows from operating activities:	'	'
Net income	$240,572	$239,594
Depreciation and amortization	95,647	93,586
Decrease in operating capital	-60,938	-80,902
Other non-cash items	27,486	13,306
Net cash provided by operating activities	302,767	265,584
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-177,936	-106,062
Acquisitions of businesses, net of cash acquired, and other	754	-8,997
Insurance proceeds received	1,359	1,254
Net cash used in investing activities	-175,823	-113,805
Cash flows from financing activities:	'	'
Proceeds from long-term debt	1,362,900	975,000
Repayments of long-term debt	-1,363,061	-1,108,034
Net (repayments of) proceeds from short-term debt	-3,735	8,380
Repurchase of common stock	-50,000	-44,363
Proceeds related to share-based compensation awards	6,880	19,094
Excess tax benefit from share-based compensation awards	15,000	15,700
Purchase of Origio shares from noncontrolling interests	0	-2,641
Dividends on common stock	-1,436	-1,449
Distributions to noncontrolling interests	-1,678	-1,007
Payment of contingent consideration	-3,820	-3,600
Proceeds from construction allowance	8,865	4,781
Net cash used in financing activities	-30,085	-138,139
Effect of exchange rate changes on cash and cash equivalents	-466	-998
Net increase in cash and cash equivalents	96,393	12,642
Cash and cash equivalents - beginning of period	77,393	12,840
Cash and cash equivalents - end of period	$173,786	$25,482

General

General	9 Months Ended
	Jul. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
General	'
	General
	The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO). Cooper is dedicated to being A Quality of Life CompanyTM with a focus on delivering shareholder value. Cooper operates through our business units, CooperVision and CooperSurgical.
	•	CooperVision develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market.
	•	CooperSurgical develops, manufactures and markets medical devices and procedure solutions to improve healthcare delivery to women.
	The unaudited consolidated condensed financial statements presented in this report contain all adjustments necessary to present fairly Cooper’s consolidated condensed financial position at July 31, 2014 and October 31, 2013, the consolidated results of its operations for the three and nine months ended July 31, 2014 and 2013 and its consolidated condensed cash flows for the nine months ended July 31, 2014 and 2013. Most of these adjustments are normal and recurring. However, certain adjustments associated with acquisitions and insurance proceeds are of a nonrecurring nature. Readers should not assume that the results reported here either indicate or guarantee future performance.
	During interim periods, we follow the accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2013. Please refer to this when reviewing this Quarterly Report on Form 10-Q.
	On October 28, 2011, a manufacturing building in the United Kingdom (UK) experienced an incident in which a pipe broke in our fire suppression system, causing water and fire retardant foam damage to the facility. While this incident did not substantially impact our existing customers, the repairs to the facility and resultant decrease in manufacturing capacity impacted the timing of marketing initiatives to generate additional sales. In January 2013, we resolved our business interruption claim with our insurer for a total of $19.1 million. We received payments of $5.0 million in our fiscal fourth quarter of 2012. In our fiscal first quarter of 2013, we recorded the remaining $14.1 million in our Consolidated Statement of Income of which we received payment of $2.9 million during the fiscal first quarter 2013 and the remaining $11.2 million in the fiscal second quarter 2013.
	Management estimates and judgments are an integral part of financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). We believe that the critical accounting policies listed below address the more significant estimates required of Management when preparing our consolidated financial statements in accordance with GAAP. We consider an accounting estimate critical if changes in the estimate may have a material impact on our financial condition or results of operations. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, actual results could differ from the original estimates, requiring adjustment to these balances in future periods. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are:
	•Revenue recognition
	•Net realizable value of inventory
	•Valuation of goodwill
	•Business combinations
	•Income taxes
	•Share-based compensation
	During the fiscal first nine months of 2014, there were no significant changes in our estimates and critical accounting policies. Please refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended October 31, 2013, for a more complete discussion of our estimates and critical accounting policies.
	Accounting Pronouncements Issued Not Yet Adopted
	In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 requires an unrecognized tax benefit to be presented in the financial statements as a reduction to a deferred tax asset when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. When a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available, or the entity does not intend to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The Company does not anticipate the adoption of these amendments, which are effective for the Company for the fiscal year beginning on November 1, 2014, will have a material impact on our consolidated results of operations, financial condition or cash flows.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 requires revenue recognition to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the update recognized at the date of the initial application along with additional disclosures. The Company is currently evaluating the impact of ASU 2014-09, which is effective for the Company in our fiscal year beginning on November 1, 2017.

Inventories

Inventories	9 Months Ended
	Jul. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	(In thousands)	July 31, 2014		31-Oct-13
	Raw materials	$	80,111	$	79,331
	Work-in-process	13,908		10,515
	Finished goods	259,365		249,071
		$	353,384	$	338,917
	Inventories are stated at the lower of cost or market. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible_Assets

Intangible Assets	9 Months Ended
	Jul. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	Intangible Assets
	Goodwill
	(In thousands)	CooperVision		CooperSurgical			Total
	Balance as of October 31, 2012	$	1,044,054	$	326,193		$	1,370,247
	Net additions during the year ended October 31, 2013	3,363		11,017			14,380
	Translation	1,061		1,923			2,984
	Balance as of October 31, 2013	1,048,478		339,133			1,387,611
	Net reductions during the nine-month period ended July 31, 2014	—		(590		)	(590		)
	Translation	5,070		(1,180		)	3,890
	Balance as of July 31, 2014	$	1,053,548	$	337,363		$	1,390,911
	We performed our annual impairment assessment in our fiscal third quarter of 2014, and our analysis indicated that we had no impairment of goodwill. We performed our annual impairment assessment in our fiscal third quarter of 2013, and our analysis indicated that we had no impairment of goodwill. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards.
	In fiscal 2014 and 2013, we performed a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the two step impairment test will be performed. Initially, we compare the book value of net assets to the fair value of each reporting unit that has goodwill assigned to it. If the fair value is determined to be less than the book value, a second step is performed to compute the amount of the impairment. A reporting unit is the level of reporting at which goodwill is tested for impairment. Our reporting units are the same as our business segments - CooperVision and CooperSurgical - reflecting the way that we manage our business.
	Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or a future downturn in our business, or a future annual goodwill impairment test indicates an impairment of our goodwill, the Company may have to recognize a non-cash impairment of its goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets, stockholders' equity and financial condition.
	Other Intangible Assets
		As of July 31, 2014					As of October 31, 2013
	(In thousands)	Gross Carrying		Accumulated			Gross Carrying			Accumulated
		Amount		Amortization			Amount			Amortization
				& Translation						& Translation
	Trademarks	$	12,251	$	2,672		$	12,481		$	2,337
	Technology	128,309		87,755			133,842			84,371
	Shelf space and market share	199,457		87,488			199,379			75,700
	License and distribution rights and other	24,394		10,204			24,947			9,472
		364,411		$	188,119		370,649			$	171,880
	Less accumulated amortization and translation	188,119					171,880
	Other intangible assets, net	$	176,292				$	198,769
	We estimate that amortization expense for our other intangible assets at July 31, 2014, will be $28.5 million in fiscal 2014, $22.0 million in fiscal 2015, $20.4 million in fiscal 2016, $19.6 million in fiscal 2017 and $17.7 million in fiscal 2018.

Debt

Debt	9 Months Ended
	Jul. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	(In thousands)	July 31, 2014		31-Oct-13
	Short-term:
	Overdraft and other credit facilities	$	46,492	$	42,987
	Long-term:
	Credit agreement	$	—	$	—
	Term Loan	300,000		300,000
	Other	1,449		1,670
		$	301,449	$	301,670
	Credit Agreement
	On May 31, 2012, Cooper entered into an amendment to our Credit Agreement, dated as of January 12, 2011, by and among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The Credit Agreement, as amended, provides for a multicurrency revolving credit facility in an aggregate commitment amount of $1.0 billion and the aggregate commitment amount under the revolving facility may be increased, upon written request by Cooper, by $500.0 million. The amended Credit Agreement has a termination date of May 31, 2017.
	The commitment fee rate ranges between 0.100% and 0.275% of the unused portion of the revolving facility based on a pricing grid tied to our Total Leverage Ratio (as defined below and in the Credit Agreement). The applicable margin rates on loans outstanding under the Credit Agreement will bear interest based, at our option, on either the base rate or the adjusted Eurodollar rate (currently referred to as LIBOR) or adjusted foreign currency rate (each as defined in the amended Credit Agreement), plus an applicable margin of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted Eurodollar rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to our Total Leverage Ratio, as defined in the Credit Agreement. In addition to the annual commitment fee, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the Credit Agreement.
	The Credit Agreement is not secured by any of the Company's, or any of its subsidiaries’, assets. All obligations under the Credit Agreement will be guaranteed by each of our existing and future direct and indirect material domestic subsidiaries.
	Pursuant to the terms of the Credit Agreement and the term loans discussed below, we are also required to maintain specified financial ratios:
	•	The ratio of Consolidated Proforma EBITDA to Consolidated Interest Expense (as defined, Interest Coverage Ratio) be at least 3.00 to 1.00 at all times.
	•	The ratio of Consolidated Funded Indebtedness to Consolidated Proforma EBITDA (as defined, Total Leverage Ratio) be no higher than 3.75 to 1.00.
	At July 31, 2014, we were in compliance with the Interest Coverage Ratio at 78.88 to 1.00 and the Total Leverage Ratio at 0.67 to 1.00.
	At July 31, 2014, we had $999.8 million available under the Credit Agreement.
	Term Loan
	On September 12, 2013, the Company entered into a five-year, $300.0 million, senior unsecured term loan agreement by and among the Company; the lenders party thereto and KeyBank National Association, as administrative agent. This syndicated credit facility will mature on September 12, 2018, and will be subject to amortization of principal of 5% per annum payable quarterly beginning October 31, 2016, with the balance payable at maturity.
	Amounts outstanding under this term loan agreement will bear interest, at the Company's option, at either the base rate, which is a rate per annum equal to the greatest of (a) KeyBank's prime rate, (b) 0.5% in excess of the federal funds effective rate and (c) 1% in excess of the adjusted Eurodollar rate (currently referred to as LIBOR) for a one-month interest period on such day, or the adjusted Eurodollar rate, plus, in each case, an applicable margin of, initially, 0%, in respect of base rate loans and 0.75%, in respect of adjusted Eurodollar rate loans. The applicable margins will be determined quarterly by reference to a grid based upon the Company's ratio of funded debt to consolidated proforma EBITDA, or Total Leverage Ratio as defined in the term loan agreement, and consistent with the revolving Credit Agreement discussed above.
	This term loan agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, as defined in the agreement, consistent with the revolving Credit Agreement discussed above. The agreement also contains customary events of default, the occurrence of which would permit the Administrative Agent to declare the principal, accrued interest and other obligations of the Company under the agreement to be immediately due and payable.
	At July 31, 2014, we had $300.0 million outstanding under the Term Loan.
	$700.0 million Term Loan on August 4, 2014
	On August 4, 2014, after the end of our fiscal third quarter of 2014, we entered into a three-year, $700.0 million, senior unsecured term loan agreement by and among the Company, the lenders party thereto and KeyBank National Association as administrative agent. This syndicated credit facility will mature and the balance is payable on August 4, 2017. There is no amortization of principal and we may prepay loan balances from time to time, in whole or in part, without premium or penalty.
	Amounts outstanding under this term loan agreement will bear interest, at the Company’s option, at either the base rate, which is a rate per annum equal to the greatest of (a) KeyBank’s prime rate, (b) 0.5% in excess of the federal funds effective rate and (c) 1% in excess of the adjusted Eurodollar rate (currently referred to as LIBOR) for a one-month interest period on such day, or the adjusted Eurodollar rate, plus, in each case, an applicable margin. The applicable margins will be determined quarterly by reference to a grid based upon the Company’s ratio of funded debt to consolidated pro forma EBITDA, as defined in the term loan agreement and consistent with the revolving Credit Agreement.
	This term loan agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the agreement, and consistent with the revolving Credit Agreement. This term loan agreement also contains customary events of default, the occurrence of which would permit the Administrative Agent to declare the principal, accrued interest and other obligations of the Company under the agreement to be immediately due and payable.
	This term loan was not outstanding at July 31, 2014. In August 2014, we utilized this facility to fund the acquisition of Sauflon Pharmaceuticals Limited, as well as to provide working capital and for general corporate purposes.

Income_Taxes

Income Taxes	9 Months Ended
	Jul. 31, 2014
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]	'
Income Taxes	'
	Income Taxes
	Our effective tax rate (ETR) (provision for income taxes divided by pretax income) for the fiscal first nine months of 2014 was 8.1%. Our year-to-date results reflect the projected fiscal year ETR, plus any discrete items. The ETR used to record the provision for income taxes for the fiscal first nine months of 2013 was 4.6%. The ETR is below the United States statutory rate as a majority of our taxable income is earned in foreign jurisdictions with lower tax rates.
	We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. At November 1, 2013, Cooper had unrecognized tax benefits, that if recognized, $28.8 million would impact our ETR. For the nine-month period ended July 31, 2014, there were no material changes to the total amount of unrecognized tax benefits.
	Interest and penalties of $2.6 million have been reflected as a component of the total liability at November 1, 2013. It is the Company’s policy to recognize the items of interest and penalties directly related to income taxes as additional income tax expense.
	Included in the balance of unrecognized tax benefits at November 1, 2013, is $3.6 million related to tax positions for which it is reasonably possible that the total amounts could significantly change during the next twelve months. This amount represents a decrease in unrecognized tax benefits related to expiring statutes in various jurisdictions worldwide and relates primarily to transfer pricing matters.
	At July 31, 2014, the tax years for which Cooper remains subject to United States Federal income tax assessment upon examination are 2010 through 2013. Cooper remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2010 through 2013.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Jul. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	Periods Ended July 31,	Three Months				Nine Months
	(In thousands, except per share amounts)	2014		2013		2014		2013
	Net income attributable to Cooper stockholders	$	88,067	$	88,951	$	239,070	$	238,754
	Basic:
	Weighted average common shares	48,042		48,791		47,990		48,588
	Basic earnings per common share attributable to Cooper stockholders	$	1.83	$	1.82	$	4.98	$	4.91
	Diluted:
	Weighted average common shares	48,042		48,791		47,990		48,588
	Effect of potential dilutive common shares	880		963		911		1,035
	Diluted weighted average common shares	48,922		49,754		48,901		49,623
	Diluted earnings per common share attributable to Cooper stockholders	$	1.8	$	1.79	$	4.89	$	4.81
	The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:
	Periods Ended July 31,	Three Months				Nine Months
	(In thousands, except exercise prices)	2014		2013		2014		2013
	Numbers of stock option shares excluded	138		—		138		—
	Range of exercise prices	$	119.89	$	—	$	119.89	$	—
	Numbers of restricted stock units excluded	—		—		1		—

ShareBased_Compensation_Plans

Share-Based Compensation Plans	9 Months Ended
	Jul. 31, 2014
Share-based Compensation [Abstract]	'
Share-Based Compensation Plans	'
	Share-Based Compensation Plans
	Cooper has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2013. The compensation expense and related income tax benefit recognized in our consolidated financial statements for share-based awards were as follows:
	Periods Ended July 31,	Three Months				Nine Months
	(In millions)	2014		2013		2014		2013
	Selling, general and administrative expense	$	6.4	$	5.5	$	26.2	$	19.6
	Cost of sales	0.5		0.5		1.8		1.5
	Research and development expense	0.5		0.3		1.5		0.9
	Capitalized in inventory	0.5		0.5		1.8		1.5
	Total share-based compensation expense	$	7.9	$	6.8	$	31.3	$	23.5
	Related income tax benefit	$	2.3	$	1.9	$	9.6	$	6.9

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Jul. 31, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Analysis of Changes in Accumulated Other Comprehensive Income (Loss):
	(In thousands)	Foreign Currency Translation Adjustment			Unrealized Gain on Marketable Securities			Change in Value of			Minimum Pension Liability			Total
								Derivative Instruments
	Balance at October 31, 2013	$	(4,592	)	$	—		$	(1,033	)	$	(10,137	)	$	(15,762	)
	Gross change in value for the period	14,168			—			(58		)	22			14,132
	Reclassification adjustments for loss realized in net income	—			—			1,445			—			1,445
	Tax effect for the period	—			—			(541		)	—			(541		)
	Balance at July 31, 2014	$	9,576		$	—		$	(187	)	$	(10,115	)	$	(726	)
	Balance at October 31, 2012	$	(7,199	)	$	50		$	(2,374	)	$	(21,738	)	$	(31,261	)
	Gross change in value for the period	(26,108		)	121			(187		)	22			(26,152		)
	Reclassification adjustments for (gain) loss realized in net income	—			(146		)	1,847			—			1,701
	Tax effect for the period	—			(29		)	(647		)	—			(676		)
	Balance at July 31, 2013	$	(33,307	)	$	(4	)	$	(1,361	)	$	(21,716	)	$	(56,388	)
	Share Repurchases
	In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and subsequently amended the total repurchase authorization to $500.0 million of the Company’s common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. The Company did not repurchase shares during the three-month periods ended July 31, 2014, July 31, 2013, April 30, 2014 and April 30, 2013. For the three months ended January 31, 2014, the Company repurchased 396 thousand shares of the Company’s common stock for $50.0 million at an average purchase price of $126.21 per share. During the three months ended January 31, 2013, the Company repurchased 460 thousand shares for $44.4 million, at an average purchase price of $96.34 per share. At July 31, 2014, approximately $211.5 million remains authorized for repurchase under the program.
	Dividends
	We paid a semiannual dividend of approximately $1.4 million or 3 cents per share on February 7, 2014, to stockholders of record on January 24, 2014. We paid another semiannual dividend of approximately $1.5 million or 3 cents per share on August 6, 2014, to stockholders of record on July 24, 2014.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Jul. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	At July 31, 2014 and October 31, 2013, the carrying value of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms.
	Assets and liabilities are measured and reported at fair value per related accounting standards that define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
	The Company has derivative assets and liabilities that include interest rate swaps, cross currency swaps and foreign currency forward contracts. The impact of the counterparty’s creditworthiness when in an asset position and Cooper’s creditworthiness when in a liability position has also been factored into the fair value measurement of the derivative instruments. Both the counterparty and Cooper are expected to continue to perform under the contractual terms of the instruments.
	We may use interest rate swaps to maintain our desired mix of fixed-rate and variable-rate debt. The swaps exchange fixed and variable rate payments without exchanging the notional principal amount of the debt. We have elected to use the income approach to value the derivatives using observable Level 2 market expectations at the measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated but not compelled to transact. Level 2 inputs are limited to quoted prices for similar assets or liabilities in active markets, specifically Eurodollar futures contracts up to three years, and inputs other than quoted prices that are observable for the asset or liability - specifically LIBOR cash and swap rates and credit risk at commonly quoted intervals. Mid-market pricing is used as a practical expedient for fair value measurements.
	We may use foreign exchange forward contracts to minimize, to the extent reasonable and practical, our exposure to the impact of foreign currency fluctuations. We have elected to use the income approach to value the derivatives using observable Level 2 market expectations at the measurement date and standard valuation techniques to convert future amounts to a single present amount assuming that participants are motivated but not compelled to transact. Level 2 inputs for the valuations are limited to quoted prices for similar assets or liabilities in active markets and inputs other than quoted prices that are observable for the asset or liability - specifically LIBOR cash rates, credit risk at commonly quoted intervals, foreign exchange spot rates and forward points. Mid-market pricing is used as a practical expedient for fair value measurements.
	The following table sets forth our financial assets and liabilities that were measured at fair value on a recurring basis using Level 2 inputs during the fiscal first nine months of 2014, within the fair value hierarchy at July 31, 2014, and fiscal year 2013, within the fair value hierarchy at October 31, 2013:
	(In millions)	July 31, 2014		31-Oct-13
	Assets:
	Foreign exchange contracts	$	0.4	$	0.3
	Liabilities:
	Interest rate swaps	$	0.3	$	1.7
	Foreign exchange contracts	—		0.6
		$	0.3	$	2.3
	We recorded contingent consideration representing the estimated fair value of the additional variable cash consideration payable related to an acquisition in our fiscal first quarter of 2013. We recorded the fair value of the acquisition-related contingent consideration as liabilities on the acquisition date using the discounted cash flow approach. Cooper uses unobservable Level 3 inputs including a forecast of new customer accounts and discount rates to fair value the liabilities. Significant changes in these unobservable inputs in isolation may result in a significantly lower or higher fair value measurement. At July 31, 2014, the fair value of the contingent consideration payable totaled $2.1 million.

Employee_Benefits

Employee Benefits	9 Months Ended
	Jul. 31, 2014
General Discussion of Pension and Other Postretirement Benefits [Abstract]	'
Employee Benefits	'
	Employee Benefits
	Cooper’s Retirement Income Plan (Plan), a defined benefit plan, covers substantially all full-time United States employees. Cooper’s contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.
	Cooper’s results of operations for the three and nine months ended July 31, 2014 and 2013 reflect the following components of net periodic pension costs:
	Periods Ended July 31,	Three Months						Nine Months
	(In thousands)	2014			2013			2014			2013
	Service cost	$	1,768		$	1,845		$	5,305		$	5,537
	Interest cost	988			822			2,963			2,465
	Expected returns on assets	(1,237		)	(1,028		)	(3,712		)	(2,950		)
	Amortization of prior service cost	6			6			18			18
	Recognized net actuarial loss	154			547			462			1,640
	Net periodic pension cost	$	1,679		$	2,192		$	5,036		$	6,710
	Cooper contributed $1.4 million and $5.8 million to the pension plan for the three and nine months ended July 31, 2014, respectively, and expects to contribute an additional $3.0 million in fiscal 2014. We contributed $1.1 million and $4.5 million to the pension plan for the three and nine months ended July 31, 2013. The expected rate of return on plan assets for determining net periodic pension cost is 8%.

Business_Segment_Information

Business Segment Information	9 Months Ended
	Jul. 31, 2014
Segment Reporting [Abstract]	'
Business Segment Information	'
	Business Segment Information
	Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results.
	Identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets. Long-lived assets are property, plant and equipment.
	Segment information:
	Periods Ended July 31,	Three Months						Nine Months
	(In thousands)	2014			2013			2014			2013
	CooperVision net sales by category:
	Toric lens	$	112,330		$	101,494		$	318,290		$	289,856
	Multifocal lens	38,393			33,085			107,627			89,890
	Single-use sphere lens	73,834			70,709			214,310			199,918
	Non single-use sphere and other	125,343			125,232			367,058			361,583
	Total CooperVision net sales	349,900			330,520			1,007,285			941,247
	CooperSurgical net sales	82,582			81,473			242,494			234,626
	Total net sales	$	432,482		$	411,993		$	1,249,779		$	1,175,873
	Operating income (loss):
	CooperVision	$	88,386		$	87,978		$	255,150		$	234,346
	CooperSurgical	18,419			16,429			50,673			42,910
	Corporate	(10,240		)	(10,799		)	(38,712		)	(33,354		)
	Total operating income	96,565			93,608			267,111			243,902
	Interest expense	1,499			2,258			4,713			7,268
	Gain on insurance proceeds	—			—			—			14,084
	Other expense (income), net	683			86			739			(461		)
	Income before income taxes	$	94,383		$	91,264		$	261,659		$	251,179
	(In thousands)	July 31, 2014			31-Oct-13
	Identifiable assets:
	CooperVision	$	2,528,420		$	2,376,022
	CooperSurgical	613,730			632,844
	Corporate	225,224			128,395
	Total	$	3,367,374		$	3,137,261
	Geographic information:
	Periods Ended July 31,	Three Months						Nine Months
	(In thousands)	2014			2013			2014			2013
	Net sales to external customers by country of domicile:
	United States	$	196,032		$	192,034		$	573,282		$	548,106
	Europe	145,543			126,215			406,007			347,676
	Rest of world	90,907			93,744			270,490			280,091
	Total	$	432,482		$	411,993		$	1,249,779		$	1,175,873
	(In thousands)	July 31, 2014			31-Oct-13
	Long-lived assets by country of domicile:
	United States	$	473,694		$	427,560
	Europe	333,306			297,157
	Rest of world	36,413			15,150
	Total	$	843,413		$	739,867

Subsequent_Events

Subsequent Events	9 Months Ended
	Jul. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	On August 6, 2014, we completed the acquisition of Sauflon Pharmaceuticals Limited (Sauflon), a privately-held European manufacturer and distributor of soft contact lenses and aftercare solutions. The acquisition of Sauflon expands our contact lens product portfolio particularly with their clariti® 1day brand of single-use sphere, toric and multifocal silicone hydrogel lenses. Clariti lenses received United States FDA clearance in August 2013. Sauflon is headquartered in the UK and has a global presence, with manufacturing facilities in the UK and Hungary.
	We paid approximately $1.2 billion consisting of approximately $1,075.0 million in cash, including a net debt adjustment amount; approximately $58.0 million in the form of loan notes; and we also assumed third-party debt of Sauflon of approximately $79.0 million that we repaid concurrent with the acquisition. We financed the acquisition with available offshore cash and credit facilities along with funds from the new $700.0 million term loan facility described in Note 4 and below. We are in the process of determining the purchase price allocation for this acquisition.
	This acquisition is consistent with our strategy to expand CooperVision’s presence in underpenetrated areas particularly the single-use silicone hydrogel lens market. We expect the acquisition to accelerate the growth of our single-use franchise by enabling a multi-tier, single-use strategy with a full suite of hydrogel and silicone hydrogel product offerings in the major product categories of sphere, toric and multifocal lenses. We also expect this acquisition to provide for an enhanced relationship with key European retailers and opportunities for operational synergies.
	On August 4, 2014, we entered into a three-year, $700.0 million senior unsecured term loan agreement by and among the Company, the lenders party thereto and KeyBank National Association as administrative agent. This syndicated credit facility will mature and the balance is payable on August 4, 2017. There is no amortization of principal and we may prepay loan balances from time to time, in whole or in part, without premium or penalty.
	We utilized this facility to fund the acquisition of Sauflon Pharmaceuticals Limited, as well as to provide working capital and for general corporate purposes.
	Amounts outstanding under this term loan agreement will bear interest, at the Company’s option, at either the base rate, which is a rate per annum equal to the greatest of (a) KeyBank’s prime rate, (b) 0.5% in excess of the federal funds effective rate and (c) 1% in excess of the adjusted Eurodollar rate (currently referred to as LIBOR) for a one-month interest period on such day, or the adjusted Eurodollar rate, plus, in each case, an applicable margin. The applicable margins will be determined quarterly by reference to a grid based upon the Company’s ratio of funded debt to consolidated pro forma EBITDA, as defined in the term loan agreement and consistent with our existing revolving Credit Agreement.
	This term loan agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the agreement, and consistent with our existing revolving Credit Agreement. This term loan agreement also contains customary events of default, the occurrence of which would permit the Administrative Agent to declare the principal, accrued interest and other obligations of the Company under the agreement to be immediately due and payable.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Jul. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	(In thousands)	July 31, 2014		31-Oct-13
	Raw materials	$	80,111	$	79,331
	Work-in-process	13,908		10,515
	Finished goods	259,365		249,071
		$	353,384	$	338,917

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Jul. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill	'
	Goodwill
	(In thousands)	CooperVision		CooperSurgical			Total
	Balance as of October 31, 2012	$	1,044,054	$	326,193		$	1,370,247
	Net additions during the year ended October 31, 2013	3,363		11,017			14,380
	Translation	1,061		1,923			2,984
	Balance as of October 31, 2013	1,048,478		339,133			1,387,611
	Net reductions during the nine-month period ended July 31, 2014	—		(590		)	(590		)
	Translation	5,070		(1,180		)	3,890
	Balance as of July 31, 2014	$	1,053,548	$	337,363		$	1,390,911
Schedule of Other Intangible Assets	'
	Other Intangible Assets
		As of July 31, 2014					As of October 31, 2013
	(In thousands)	Gross Carrying		Accumulated			Gross Carrying			Accumulated
		Amount		Amortization			Amount			Amortization
				& Translation						& Translation
	Trademarks	$	12,251	$	2,672		$	12,481		$	2,337
	Technology	128,309		87,755			133,842			84,371
	Shelf space and market share	199,457		87,488			199,379			75,700
	License and distribution rights and other	24,394		10,204			24,947			9,472
		364,411		$	188,119		370,649			$	171,880
	Less accumulated amortization and translation	188,119					171,880
	Other intangible assets, net	$	176,292				$	198,769

Debt_Tables

Debt (Tables)	9 Months Ended
	Jul. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt	'
	(In thousands)	July 31, 2014		31-Oct-13
	Short-term:
	Overdraft and other credit facilities	$	46,492	$	42,987
	Long-term:
	Credit agreement	$	—	$	—
	Term Loan	300,000		300,000
	Other	1,449		1,670
		$	301,449	$	301,670

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Jul. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share	'
	Periods Ended July 31,	Three Months				Nine Months
	(In thousands, except per share amounts)	2014		2013		2014		2013
	Net income attributable to Cooper stockholders	$	88,067	$	88,951	$	239,070	$	238,754
	Basic:
	Weighted average common shares	48,042		48,791		47,990		48,588
	Basic earnings per common share attributable to Cooper stockholders	$	1.83	$	1.82	$	4.98	$	4.91
	Diluted:
	Weighted average common shares	48,042		48,791		47,990		48,588
	Effect of potential dilutive common shares	880		963		911		1,035
	Diluted weighted average common shares	48,922		49,754		48,901		49,623
	Diluted earnings per common share attributable to Cooper stockholders	$	1.8	$	1.79	$	4.89	$	4.81
Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation	'
	The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:
	Periods Ended July 31,	Three Months				Nine Months
	(In thousands, except exercise prices)	2014		2013		2014		2013
	Numbers of stock option shares excluded	138		—		138		—
	Range of exercise prices	$	119.89	$	—	$	119.89	$	—
	Numbers of restricted stock units excluded	—		—		1		—

ShareBased_Compensation_Plans_

Share-Based Compensation Plans (Tables)	9 Months Ended
	Jul. 31, 2014
Share-based Compensation [Abstract]	'
Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards	'
	The compensation expense and related income tax benefit recognized in our consolidated financial statements for share-based awards were as follows:
	Periods Ended July 31,	Three Months				Nine Months
	(In millions)	2014		2013		2014		2013
	Selling, general and administrative expense	$	6.4	$	5.5	$	26.2	$	19.6
	Cost of sales	0.5		0.5		1.8		1.5
	Research and development expense	0.5		0.3		1.5		0.9
	Capitalized in inventory	0.5		0.5		1.8		1.5
	Total share-based compensation expense	$	7.9	$	6.8	$	31.3	$	23.5
	Related income tax benefit	$	2.3	$	1.9	$	9.6	$	6.9

Stockholders_Equity_Analysis_o

Stockholders' Equity Analysis of Changes in Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Jul. 31, 2014
Equity [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	Analysis of Changes in Accumulated Other Comprehensive Income (Loss):
	(In thousands)	Foreign Currency Translation Adjustment			Unrealized Gain on Marketable Securities			Change in Value of			Minimum Pension Liability			Total
								Derivative Instruments
	Balance at October 31, 2013	$	(4,592	)	$	—		$	(1,033	)	$	(10,137	)	$	(15,762	)
	Gross change in value for the period	14,168			—			(58		)	22			14,132
	Reclassification adjustments for loss realized in net income	—			—			1,445			—			1,445
	Tax effect for the period	—			—			(541		)	—			(541		)
	Balance at July 31, 2014	$	9,576		$	—		$	(187	)	$	(10,115	)	$	(726	)
	Balance at October 31, 2012	$	(7,199	)	$	50		$	(2,374	)	$	(21,738	)	$	(31,261	)
	Gross change in value for the period	(26,108		)	121			(187		)	22			(26,152		)
	Reclassification adjustments for (gain) loss realized in net income	—			(146		)	1,847			—			1,701
	Tax effect for the period	—			(29		)	(647		)	—			(676		)
	Balance at July 31, 2013	$	(33,307	)	$	(4	)	$	(1,361	)	$	(21,716	)	$	(56,388	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jul. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Level 2 Inputs	'
	The following table sets forth our financial assets and liabilities that were measured at fair value on a recurring basis using Level 2 inputs during the fiscal first nine months of 2014, within the fair value hierarchy at July 31, 2014, and fiscal year 2013, within the fair value hierarchy at October 31, 2013:
	(In millions)	July 31, 2014		31-Oct-13
	Assets:
	Foreign exchange contracts	$	0.4	$	0.3
	Liabilities:
	Interest rate swaps	$	0.3	$	1.7
	Foreign exchange contracts	—		0.6
		$	0.3	$	2.3

Employee_Benefits_Tables

Employee Benefits (Tables)	9 Months Ended
	Jul. 31, 2014
General Discussion of Pension and Other Postretirement Benefits [Abstract]	'
Schedule of Components of Net Periodic Pension Costs	'
	Cooper’s results of operations for the three and nine months ended July 31, 2014 and 2013 reflect the following components of net periodic pension costs:
	Periods Ended July 31,	Three Months						Nine Months
	(In thousands)	2014			2013			2014			2013
	Service cost	$	1,768		$	1,845		$	5,305		$	5,537
	Interest cost	988			822			2,963			2,465
	Expected returns on assets	(1,237		)	(1,028		)	(3,712		)	(2,950		)
	Amortization of prior service cost	6			6			18			18
	Recognized net actuarial loss	154			547			462			1,640
	Net periodic pension cost	$	1,679		$	2,192		$	5,036		$	6,710

Business_Segment_Information_T

Business Segment Information (Tables)	9 Months Ended
	Jul. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Information	'
	Segment information:
	Periods Ended July 31,	Three Months						Nine Months
	(In thousands)	2014			2013			2014			2013
	CooperVision net sales by category:
	Toric lens	$	112,330		$	101,494		$	318,290		$	289,856
	Multifocal lens	38,393			33,085			107,627			89,890
	Single-use sphere lens	73,834			70,709			214,310			199,918
	Non single-use sphere and other	125,343			125,232			367,058			361,583
	Total CooperVision net sales	349,900			330,520			1,007,285			941,247
	CooperSurgical net sales	82,582			81,473			242,494			234,626
	Total net sales	$	432,482		$	411,993		$	1,249,779		$	1,175,873
	Operating income (loss):
	CooperVision	$	88,386		$	87,978		$	255,150		$	234,346
	CooperSurgical	18,419			16,429			50,673			42,910
	Corporate	(10,240		)	(10,799		)	(38,712		)	(33,354		)
	Total operating income	96,565			93,608			267,111			243,902
	Interest expense	1,499			2,258			4,713			7,268
	Gain on insurance proceeds	—			—			—			14,084
	Other expense (income), net	683			86			739			(461		)
	Income before income taxes	$	94,383		$	91,264		$	261,659		$	251,179
Schedule of Identifiable Assets by Segment	'
	(In thousands)	July 31, 2014			31-Oct-13
	Identifiable assets:
	CooperVision	$	2,528,420		$	2,376,022
	CooperSurgical	613,730			632,844
	Corporate	225,224			128,395
	Total	$	3,367,374		$	3,137,261
Schedule of Net Sales to External Customers by Country of Domicile	'
	Geographic information:
	Periods Ended July 31,	Three Months						Nine Months
	(In thousands)	2014			2013			2014			2013
	Net sales to external customers by country of domicile:
	United States	$	196,032		$	192,034		$	573,282		$	548,106
	Europe	145,543			126,215			406,007			347,676
	Rest of world	90,907			93,744			270,490			280,091
	Total	$	432,482		$	411,993		$	1,249,779		$	1,175,873
Schedule of Long-Lived Assets by Country of Domicile	'
	(In thousands)	July 31, 2014			31-Oct-13
	Long-lived assets by country of domicile:
	United States	$	473,694		$	427,560
	Europe	333,306			297,157
	Rest of world	36,413			15,150
	Total	$	843,413		$	739,867

General_Details

General (Details) (USD $)	1 Months Ended	3 Months Ended					9 Months Ended
	Jan. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Oct. 31, 2012	Jul. 31, 2014	Jul. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'	'	'	'	'
Insurance proceeds	$19,100,000	$0	$0	'	$14,100,000	'	$0	$14,084,000
Proceeds from Insurance Settlement, Operating Activities	'	'	'	$11,200,000	$2,900,000	$5,000,000	'	'

Inventories_Schedule_of_Invent

Inventories (Schedule of Inventories) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$80,111	$79,331
Work-in-process	13,908	10,515
Finished goods	259,365	249,071
Inventories, net	$353,384	$338,917

Intangible_Assets_Schedule_of_

Intangible Assets (Schedule of Goodwill) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Oct. 31, 2013
Goodwill [Roll Forward]	'	'
Balance, beginning	$1,387,611	$1,370,247
Net additions during the year	'	14,380
Net reductions during the nine-month period ended July 31, 2014	-590	'
Translation	3,890	2,984
Balance, ending	1,390,911	1,387,611
CooperVision [Member]	'	'
Goodwill [Roll Forward]	'	'
Balance, beginning	1,048,478	1,044,054
Net additions during the year	'	3,363
Net reductions during the nine-month period ended July 31, 2014	0	'
Translation	5,070	1,061
Balance, ending	1,053,548	1,048,478
CooperSurgical [Member]	'	'
Goodwill [Roll Forward]	'	'
Balance, beginning	339,133	326,193
Net additions during the year	'	11,017
Net reductions during the nine-month period ended July 31, 2014	-590	'
Translation	-1,180	1,923
Balance, ending	$337,363	$339,133

Intangible_Assets_Schedule_of_1

Intangible Assets (Schedule of Other Intangible Assets) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$364,411	$370,649
Accumulated Amortization & Translation	188,119	171,880
Other intangible assets, net	176,292	198,769
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	12,251	12,481
Accumulated Amortization & Translation	2,672	2,337
Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	128,309	133,842
Accumulated Amortization & Translation	87,755	84,371
Shelf space and market share [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	199,457	199,379
Accumulated Amortization & Translation	87,488	75,700
License and distribution right and other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	24,394	24,947
Accumulated Amortization & Translation	$10,204	$9,472

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Goodwill, Impairment Loss	$0	$0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'	'
2014	28,500,000	'
2015	22,000,000	'
2016	20,400,000	'
2017	19,600,000	'
2018	$17,700,000	'

Debt_Schedule_of_Debt_Details

Debt (Schedule of Debt) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, unless otherwise specified
Short-term:	'	'
Overdraft and other credit facilities	$46,492	$42,987
Long-term:	'	'
Credit agreement	0	0
Term Loan	300,000	300,000
Other	1,449	1,670
Long-term debt	$301,449	$301,670

Debt_Narrative_Details

Debt (Narrative) (Details) (USD $)

9 Months Ended

0 Months Ended

Jul. 31, 2014

Oct. 31, 2013

31-May-12

31-May-12

31-May-12

Jan. 12, 2011

Sep. 12, 2013

Sep. 12, 2013

Sep. 12, 2013

Aug. 04, 2014

Aug. 04, 2014

Aug. 04, 2014

Minimum [Member]

Maximum [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Term Loan Facility [Member]

Federal Funds Rate [Member]

Eurodollar [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Federal Funds Rate [Member]

Eurodollar [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Amortization Of Term Loan Principal

'

'

'

'

'

'

5.00%

'

'

'

'

'

Debt Instrument, Date of First Required Payment

'

'

'

'

'

'

31-Oct-16

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

'

0.50%

1.00%

'

0.50%

1.00%

Line of credit facility, initiation date

'

'

'

'

'

12-Jan-11

'

'

'

'

'

'

Aggregate commitment amount of credit facility

'

'

'

'

$1,000,000,000

'

'

'

'

'

'

'

Additional borrowings

'

'

'

'

500,000,000

'

'

'

'

'

'

'

Expiration date

'

'

'

'

31-May-17

'

'

'

'

'

'

'

Commitment fee percentage

'

'

0.10%

0.28%

'

'

'

'

'

'

'

'

Line of credit facility interest rate margin on base rate loans percentage

'

'

0.00%

0.75%

'

'

0.00%

'

'

'

'

'

Line of credit facility interest rate margin on foreign currency loans percentage

'

'

1.00%

1.75%

'

'

0.75%

'

'

'

'

'

Required minimum Interest coverage ratio

3

'

'

'

'

'

'

'

'

'

'

'

Required maximum total leverage ratio

3.75

'

'

'

'

'

'

'

'

'

'

'

Interest Coverage Ratio

78.88

'

'

'

'

'

'

'

'

'

'

'

Total Leverage Ratio

0.67

'

'

'

'

'

'

'

'

'

'

'

Amount available under the credit agreement

999,800,000

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Issuance Date

'

'

'

'

'

'

12-Sep-13

'

'

4-Aug-14

'

'

Debt term

'

'

'

'

'

'

'5 years

'

'

'3 years

'

'

Term Loan

$300,000,000

$300,000,000

'

'

'

'

$300,000,000

'

'

$700,000,000

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

12-Sep-18

'

'

4-Aug-17

'

'

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Nov. 02, 2013
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]	'	'	'
Effective tax rate (ETR)	8.10%	4.60%	'
Unrecognized tax benefits that would impact ETR	'	'	$28.80
Interest and penalties	'	'	2.6
Unrecognized tax benefits related to tax positions	'	'	$3.60

Earnings_Per_Share_Schedule_of

Earnings Per Share (Schedule of Earnings Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net income attributable to Cooper stockholders	$88,067	$88,951	$239,070	$238,754
Basic:	'	'	'	'
Weighted average common shares	48,042	48,791	47,990	48,588
Basic earnings per common share attributable to Cooper stockholders	$1.83	$1.82	$4.98	$4.91
Diluted:	'	'	'	'
Effect of potential dilutive common shares	880	963	911	1,035
Diluted weighted average common shares	48,922	49,754	48,901	49,623
Diluted earnings per common share attributable to Cooper stockholders	$1.80	$1.79	$4.89	$4.81

Earnings_Per_Share_Schedule_of1

Earnings Per Share (Schedule of Stock Options to Purchase Common Stock Not Included in Diluted Net Income Per Share Calculation) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Numbers of stock option shares excluded	138	0	138	0
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$119.89	$0	$119.89	$0
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$119.89	$0	$119.89	$0
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Numbers of stock option shares excluded	0	0	1	0

ShareBased_Compensation_Plans_1

Share-Based Compensation Plans (Schedule Of Compensation Expense And Related Income Tax Benefit For Share-Based Awards) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total share-based compensation expense	$7.90	$6.80	$31.30	$23.50
Related income tax benefit	2.3	1.9	9.6	6.9
Selling, general and administrative expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	6.4	5.5	26.2	19.6
Cost of sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	0.5	0.5	1.8	1.5
Research and development expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	0.5	0.3	1.5	0.9
Capitalized in inventory [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expense	$0.50	$0.50	$1.80	$1.50

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Changes in Accumulated Other Comprehensive Income (Loss))(Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Foreign Currency Translation Adjustment [Roll Forward]	'	'	'	'
Foreign Currency Translation Adjustment, Beginning Balance	'	'	($4,592)	($7,199)
Foreign Currency Translation Adjustment, Gross change in value for the period	'	'	14,168	-26,108
Foreign Currency Translation Adjustment, Reclassification adjustments for losses realized in net income	'	'	0	0
Foreign Currency Translation Adjustment, Tax effect for the period	'	'	0	0
Foreign Currency Translation Adjustment, Ending Balance	9,576	-33,307	9,576	-33,307
Marketable Securities, Unrealized Gain (Loss) [Roll Forward]	'	'	'	'
Unrealized Gain (Loss) on Marketable Securities, Beginning Balance	'	'	0	50
Unrealized Gain (Loss) on Marketable Securities, Gross change in value for the period	'	'	0	121
Unrealized Gain (Loss) on Marketable Securities, Reclassification adjustments for losses realized in net income	'	'	0	-146
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	'	'	0	-29
Unrealized Gain (Loss) on Marketable Securities, Ending Balance	0	-4	0	-4
Change in Value of Derivative Instruments [Roll Forward]	'	'	'	'
Change in Value of Derivative Instruments, Beginning Balance	'	'	-1,033	-2,374
Change in Value of Derivative Instruments, Gross change in value for the period	'	'	-58	-187
Change in Value of Derivative Instruments, Reclassification adjustments for losses realized in net income	'	'	1,445	1,847
Change in value of derivative instruments, Tax effect for the period	-144	-260	-541	-647
Change in Value of Derivative Instruments, Ending Balance	-187	-1,361	-187	-1,361
Minimum Pension Liability [Roll Forward]	'	'	'	'
Minimum Pension Liability, Beginning Balance	'	'	-10,137	-21,738
Minimum Pension Liability, Gross change in value for the period	'	'	22	22
Minimum Pension Liability, Reclassification adjustments for losses realized in net income	'	'	0	0
Minimum Pension Liability, Tax effect for the period	0	0	0	0
Minimum Pension Liability, Ending Balance	-10,115	-21,716	-10,115	-21,716
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Total, Beginning balance	'	'	-15,762	-31,261
Gross change in value for the period	'	'	14,132	-26,152
Reclassification adjustments for loss realized in net income for the period	'	'	1,445	1,701
Tax effect for the period	'	'	-541	-676
Total, Ending balance	($726)	($56,388)	($726)	($56,388)

Stockholders_Equity_Share_Repu

Stockholders' Equity (Share Repurchases) (Details) (USD $)	3 Months Ended						9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Jul. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Jul. 31, 2013	Apr. 30, 2013	Jan. 31, 2013	Jul. 31, 2014
Equity [Abstract]	'	'	'	'	'	'	'
Share Repurchase Program, maximum amount authorized	'	'	'	'	'	'	$500
Number of common stock repurchased, shares	0	0	396	0	0	460	'
Cost of common stock repurchased	'	'	50	'	'	44.4	'
Average purchase price per share	'	'	$126.21	'	'	$96.34	'
Share Repurchase Program, remaining authorized amount	'	'	'	'	'	'	$211.50

Stockholders_Equity_Dividends_

Stockholders' Equity (Dividends) (Details) (USD $)	0 Months Ended	9 Months Ended		0 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Feb. 07, 2014	Jul. 31, 2014	Jul. 31, 2013	Aug. 06, 2014
				Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'
Dividends on common stock	$1,400	$1,436	$1,449	$1,500
Cash dividend, per share	$0.03	'	'	$0.03
Dividends payable, date of record	24-Jan-14	'	'	24-Jul-14

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis Using Level 2 Inputs) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Millions, unless otherwise specified
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of contingent consideration	$2.10	'
Significant Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of liabilities measured on a recurring basis	0.3	2.3
Significant Observable Inputs (Level 2) [Member] | Foreign Exchange Contracts [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of assets measured on a recurring basis	0.4	0.3
Fair value of liabilities measured on a recurring basis	0	0.6
Significant Observable Inputs (Level 2) [Member] | Interest Rate Swaps [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair value of liabilities measured on a recurring basis	$0.30	$1.70

Employee_Benefits_Schedule_of_

Employee Benefits (Schedule of Components of Net Periodic Pension Costs) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
General Discussion of Pension and Other Postretirement Benefits [Abstract]	'	'	'	'
Service cost	$1,768	$1,845	$5,305	$5,537
Interest cost	988	822	2,963	2,465
Expected returns on assets	-1,237	-1,028	-3,712	-2,950
Amortization of prior service cost	6	6	18	18
Recognized net actuarial loss	154	547	462	1,640
Net periodic pension cost	$1,679	$2,192	$5,036	$6,710

Employee_Benefits_Narrative_De

Employee Benefits (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
General Discussion of Pension and Other Postretirement Benefits [Abstract]	'	'	'	'
Company's contribution to the pension plan	$1.40	$1.10	$5.80	$4.50
Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year	'	'	$3	'
Expected rate of return on plan assets for determining net periodic pension cost	'	'	8.00%	'

Business_Segment_Information_S

Business Segment Information (Schedule of Segment Information) (Details) (USD $)	1 Months Ended	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	Jan. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	$432,482	$411,993	'	$1,249,779	$1,175,873
Operating income (loss)	'	96,565	93,608	'	267,111	243,902
Interest expense	'	1,499	2,258	'	4,713	7,268
Gain on insurance proceeds	19,100	0	0	14,100	0	14,084
Other expense (income), net	'	683	86	'	739	-461
Income before income taxes	'	94,383	91,264	'	261,659	251,179
CooperVision [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	349,900	330,520	'	1,007,285	941,247
Operating income (loss)	'	88,386	87,978	'	255,150	234,346
CooperSurgical [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	82,582	81,473	'	242,494	234,626
Operating income (loss)	'	18,419	16,429	'	50,673	42,910
Headquarters [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Operating income (loss)	'	-10,240	-10,799	'	-38,712	-33,354
Toric Lens [Member] | CooperVision [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	112,330	101,494	'	318,290	289,856
Multifocal Lens [Member] | CooperVision [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	38,393	33,085	'	107,627	89,890
Single-Use Sphere Lens [Member] | CooperVision [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	73,834	70,709	'	214,310	199,918
Non Single-Use Sphere And Other Eye Care Products And Other [Member] | CooperVision [Member]	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'
Net sales	'	$125,343	$125,232	'	$367,058	$361,583

Business_Segment_Information_S1

Business Segment Information (Schedule of Identifiable Assets By Segment Information) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Total Identifiable assets	$3,367,374	$3,137,261
CooperVision [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Total Identifiable assets	2,528,420	2,376,022
CooperSurgical [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Total Identifiable assets	613,730	632,844
Headquarters [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Total Identifiable assets	$225,224	$128,395

Business_Segment_Information_S2

Business Segment Information (Schedule of Net Sales To External Customers By Country Of Domicile) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Total net sales to external customers	$432,482	$411,993	$1,249,779	$1,175,873
United States [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total net sales to external customers	196,032	192,034	573,282	548,106
Europe [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total net sales to external customers	145,543	126,215	406,007	347,676
Rest Of World [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Total net sales to external customers	$90,907	$93,744	$270,490	$280,091

Business_Segment_Information_S3

Business Segment Information (Schedule of Long-Lived Assets By Country Of Domicile) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'
Total long-lived assets	$843,413	$739,867
United States [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Total long-lived assets	473,694	427,560
Europe [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Total long-lived assets	333,306	297,157
Rest Of World [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Total long-lived assets	$36,413	$15,150

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013	Sep. 12, 2013	Sep. 12, 2013	Sep. 12, 2013	Aug. 06, 2014	Aug. 04, 2014	Aug. 04, 2014	Aug. 04, 2014
			Term Loan Facility [Member]	Federal Funds Rate [Member]	Eurodollar [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Term Loan Facility [Member]	Term Loan Facility [Member]	Sauflon [Member]	Term Loan Facility [Member]	Federal Funds Rate [Member]	Eurodollar [Member]
								Term Loan Facility [Member]	Term Loan Facility [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business Acquisition, Effective Date of Acquisition	'	'	'	'	'	6-Aug-14	'	'	'
Business Combination, Consideration Transferred	'	'	'	'	'	$1,200,000,000	'	'	'
Payments to Acquire Businesses, Gross	'	'	'	'	'	1,075,000,000	'	'	'
Business Combination, Consideration Transferred, Loan Notes	'	'	'	'	'	58,000,000	'	'	'
Business Combination, Assumed Third Party Debt	'	'	'	'	'	79,000,000	'	'	'
Term Loan	$300,000,000	$300,000,000	$300,000,000	'	'	'	$700,000,000	'	'
Debt Instrument, Issuance Date	'	'	12-Sep-13	'	'	'	4-Aug-14	'	'
Debt term	'	'	'5 years	'	'	'	'3 years	'	'
Debt Instrument, Maturity Date	'	'	12-Sep-18	'	'	'	4-Aug-17	'	'
Debt Instrument, Basis Spread on Variable Rate	'	'	'	0.50%	1.00%	'	'	0.50%	1.00%